What is Hemogenyx Pharmaceuticals Plc's (HEMO.L) StockRank?

MoatMap's StockRank for Hemogenyx Pharmaceuticals Plc (HEMO.L) is 14/100, with a Strong Sell signal. This is a composite score combining Quality (14), Value (47), and Momentum (40) factor ranks across MoatMap's 20,000+ stock universe.

Does Hemogenyx Pharmaceuticals Plc have an economic moat?

Hemogenyx Pharmaceuticals Plc (HEMO.L) has a Quality factor score of 14/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Hemogenyx Pharmaceuticals Plc a buy, hold, or sell?

MoatMap's current signal for Hemogenyx Pharmaceuticals Plc (HEMO.L) is Strong Sell, based on a StockRank of 14/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Hemogenyx Pharmaceuticals Plc in?

Hemogenyx Pharmaceuticals Plc (HEMO.L) operates in the Healthcare sector, specifically the Biotechnology industry (United Kingdom).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

HEMO.L

STRONG SELLREMOVE

Hemogenyx Pharmaceuticals Plc · Healthcare · United Kingdom · $63M · Avg Vol: $187K/d

StockRank

P/E (TTM)

—

ROE

-977.7%

D/E

1.8x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Hemogenyx Pharmaceuticals is a micro-cap biotech company with no approved products and high cash burn. It is a highly speculative venture that fails all of our quality, cash flow, and margin of safety criteria.

COMPANY DESCRIPTION

Hemogenyx Pharmaceuticals Plc is a biotechnology company developing novel therapies and treatments for blood diseases, including leukemia and lymphoma. The company's pipeline includes CAR-T cell therapies and CDX bi-specific antibodies designed to improve the safety and efficacy of bone marrow transplants. Its competitive edge is rooted in its proprietary cell therapy platforms and strategic collaborations with leading global medical institutions.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	0	0	—
EPS	-2.69	-3.18	-2.43	-2.29	—
Shares	2M	3M	4M	6M	+146.6%
Debt	5M	4M	4M	3M	-16.3%
Equity	4M	4M	1M	2M	-28.5%
Op CF	-4M	-8M	-6M	-5M	—
Inv CF	-564,198	-42,881	-2,325	-9,125	—
Fin CF	-147,870	6M	4M	7M	—

PRICE (1M)+13.9%

SMA 50SMA 200

$10.70

RSI (14)

64.3

52W High

$24.17

From 52W High

0.4%

SCORE BREAKDOWN

Quality

ROIC

-352.4%0.7

ROE

-977.7%0.7

GP/Assets

—N/A

Op. Margin

0.0%40.4

FCF/Assets

-79.7%2.1

Piotroski

—28.7

Int. Cover

-41.6x13.9

D/E Ratio

1.75x6.6

Current Ratio

1.38x21.4

Value

P/E (TTM)

—N/A

EV/EBITDA

-7.4x77.9

P/FCF

—N/A

P/B

-72.4x99.5

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

44%17.6

RS 6M

19%86.6

SMA 50/200

0.89x30.0

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$63M

P/E (Forward)

—

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HEMO.L are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
HEMO.L	Hemogenyx Pharmaceuticals Plc(you)	$63M	14	STRONG SELL
SAR.L	Sareum Holdings plc	$47M	14	STRONG SELL
SBTX.L	SkinBioTherapeutics plc	$34M	21	SELL
4BB.L	4basebio PLC	$110M	5	STRONG SELL
IMM.L	ImmuPharma plc	$37M	1	STRONG SELL
APTA.L	Aptamer Group PLC	$28M	3	STRONG SELL
POLB.L	Poolbeg Pharma PLC	$56M	39	HOLD
IXI.L	IXICO plc	$25M	29	SELL
TLSA	Tiziana Life Sciences Ltd	$186M	1	STRONG SELL
BCYC	Bicycle Therapeutics plc	$326M	11	STRONG SELL

Peer medians: ROE 1.2% · P/E 26.9x · Gross margin 51.4%

Hemogenyx Pharmaceuticals Plc (HEMO.L) — Stock Score Summary

Hemogenyx Pharmaceuticals Plc (HEMO.L) has a MoatMap StockRank of 14/100 based on Quality (14/100), Value (47/100), and Momentum (40/100) factor scores. The current signal is STRONG SELL. Hemogenyx Pharmaceuticals is a micro-cap biotech company with no approved products and high cash burn. It is a highly speculative venture that fails all of our quality, cash flow, and margin of safety criteria.

Key Financial Metrics

Price	$10.70
Market Cap	$63M
Price/Book	-72.39
Return on Equity	-977.7%
Return on Invested Capital	-352.4%
Debt/Equity	175.12
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-6M

Hemogenyx Pharmaceuticals Plc operates in the Biotechnology industry, part of the Healthcare sector (United Kingdom).

Frequently Asked Questions

What is Hemogenyx Pharmaceuticals Plc’s (HEMO.L) StockRank?: MoatMap’s StockRank for Hemogenyx Pharmaceuticals Plc (HEMO.L) is 14/100, with a Strong Sell signal. It is a composite of Quality (14), Value (47), and Momentum (40) factor ranks across MoatMap’s 20,000+ stock universe.
Does Hemogenyx Pharmaceuticals Plc have an economic moat?: Hemogenyx Pharmaceuticals Plc (HEMO.L) has a Quality factor score of 14/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Hemogenyx Pharmaceuticals Plc a buy, hold, or sell?: MoatMap’s current signal for Hemogenyx Pharmaceuticals Plc (HEMO.L) is Strong Sell, based on a StockRank of 14/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Hemogenyx Pharmaceuticals Plc in?: Hemogenyx Pharmaceuticals Plc (HEMO.L) operates in the Healthcare sector, specifically the Biotechnology industry (United Kingdom).